News

TRFL Chair Bryant Reid – Selected for Lifetime Achievement of the President’s Volunteer Service Award

In recognition of his outstanding volunteer contributions in community service to the United States, Bryant Reid was selected for Lifetime Achievement of the President’s Volunteer Service Award. This prestigious recognition is a testament to his steadfast commitment, dedication, and selflessness in serving others throughout his lifetime “His tireless efforts and countless hours of volunteer work, with a primary focus in the area of securing equitable treatment and cures for those with lupus, have undoubtedly made a profound impact on the lives of many individuals and communities. With the 2018 establishment of the Reid Foundation for Lupus, Inc, the impact of his commitment will only continue to expand in the future.

 

The 2024 awards will be presented in Dallas, Texas, at the annual gala for Anna’s House Domestic Violence Shelter, scheduled to be held on Saturday, October 5, 2024. As a 2024 awardee, Mr. Reid will receive a personalized certificate, as well as a congratulatory letter from the White House, signed by President Joe Biden.”

 

 

READ MORE
News

Clinical Trial for New Lupus Treatment Opens in China

JW Therapeutics has received approval from the National Medical Products Administration of China to conduct a Phase 1 / 2 clinical trial of its CAR T-cell therapy, relmacabtagene autoleucel (relma-cel), for people with moderate to severe and/or treatment-resistant lupus. CAR T-cells are genetically altered T-cells that play a role in the immune response. Scientists create or engineer new cells called chimeric antigen receptors (CARs), and then introduce T-cells into them to create CAR-T cells.

 

READ FULL ARTICLE

 

Article Credit: Lupus Foundation of America | lupus.org

READ MORE
News

LUPKYNIS Continues to Show Promising Lupus Nephritis Outcomes

The drug treatment, LUPKYNIS® (voclosporin), reduced inflammation and prevented development of kidney damage in people with lupus nephritis (LN, lupus-related kidney disease) over 18 months. Those taking the medication also didn’t exhibit any signs of kidney-related toxicity. LUPKYINS® is a novel, structurally modified calcineurin inhibitor (CNI) that works in two ways – acting as an immunosuppressant through inhibition of T-cell activation and cytokine production, and by promoting podocyte stability in the kidney.

 

READ FULL ARTICLE

 

Article Credit: Lupus Foundation of America | lupus.org

READ MORE
News

Congratulations to Our Board Members

Congratulations to our board members, Dr. Sam Lim, Georgia State Rep. Kim Schofield and Founder Bryant Reid for being named Community Service awardees at the Phenomenal Women’s Health Annual Fundraising Tea.

 

(Pictured in the photo above l to r: Kim Schofield – Georgia State Representative, Teri Edmond – CEO of Lupus Foundation of America Georgia Chapter, Cheryl Burnside – CEO of Phenomenal Women’s Health, Bryant Reid – President of The Reid Foundation For Lupus, Inc.)

 

READ MORE
  • 1
  • 2